Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
This study has been terminated.
Study NCT00126893   Information provided by Celgene Corporation

First Received on August 3, 2005.   Last Updated on May 14, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Sponsors listed in this trial